34 results about "Etanercept" patented technology

The invention provides methods and compositions for the treatment of a skin disorder associated with detrimental TNFα activity, such as psoriasis. The invention includes methods for treating a skin disorder associated with detrimental TNFα activity, such as psoriasis, in a subject who has failed or lost response to prior biologic therapy, such as prior administration of etanercept. The invention further provides methods for determining the efficacy of a human TNFα antibody, or antigen-binding portion thereof, for the treatment of a skin disorder associated with detrimental TNFα activity, such as psoriasis.

This invention describes the administration of multiple therapeutic agents with insulin in conjunction with bexarotene, ketamine, monoclonal antibodies Etanercept, IGF-1, and acetylcholine esterase inhibitors physostigmine, for treatment of Alzheimer's disease and other neurodegenerative diseases. Insulin, improves memory; also augments and amplifies the effects of the adjuvant therapeutic agents (paracrine and intracrine effects) and consequently reduces the β amyloid, its soluble precursors, prevents damage to the neuronal skeletal network (taupathy), and blocks glutamate excitotoxicity, reduces brain inflammation, prevents apoptosis, and increases the acetylcholine levels in the neurons and synapses; by using a combination of insulin, bexarotene, ketamine, Etanercept, IGF-1, and physostigmine therapeutic agents. The results are achieved by using the specially designed Iontophoresis incorporated olfactory mucosal delivery (ORE) catheter device located at the olfactory nerves, sphenoid sinus, and adjacent structures described here, to transport the large molecules of therapeutic agents to treat AD delivered to the CNS bypassing BBB from ORE.

The invention provides stabilized aqueous pharmaceutical etanercept compositions suitable for long-term storage of etanercept, methods of manufacture of these compositions, methods of administration, and kits containing same.

The present disclosure relates to compositions and methods for treating autoimmune diseases including rheumatoid arthritis. In particular, the present disclosure relates to compositions comprising IL-6 antagonists (e.g., anti-IL6 or anti-IL6R or anti-hyperIL6) and TNF-α antagonists (e.g., (anti-TNF or etanercept) and methods of using same in the treatment of rheumatoid arthritis.

The present invention relates to novel liquid protein formulations, particularly arginine-free liquid pharmaceutical compositions of etanercept. The invention employs particular combinations and classes of buffer systems, tonicifiers, and sugar stabilisers, optionally alongside polar ionisable amino acids (e.g. aspartic acid, glutamic acid, histidine, and lysine), to afford a viable and storable drug product.

A method of using biologics to treat chronic brain injury or spasticity due to stroke, trauma and other causes. Preferred embodiments include perispinal, parenteral, transepidermal or intranasal use of TNF antagonists. The TNF antagonists include TNF receptor fusion proteins, TNF monoclonal antibodies (mAbs), humanized TNF mAbs, fully human TNF mAbs, chimeric TNF mAbs, domain TNF antibodies, mAB fragments, anti-TNF nanobodies, dominant negative TNF constructs and TNF inhibitory single chain antibody fragments. One of the preferred embodiments of this invention is the perispinal administration of etanercept for treatment of mammals following stroke. The use of Trendelenburg positioning, catheters, pumps, or depot formulations are included.

The invention discloses a western medicine composition for treating rheumatism. The western medicine composition comprises the following raw materials in parts by weight: 2-15 parts of rhizoma seu radix notopterygii, 0.1-1 part of methotrexate, 1-3 parts of soft soap, 0.1-1 part of phosphodiesterase, 1-5 parts of glucocorticoid drugs, 0.5-2 parts of etanercept, 10-50 parts of normal saline, 0.5-1 part of ossotide tablets, 1-3 parts of a donkey hide gelatin powder, 0.1-1 part of steroid and 1-3 parts of anisodamine. The raw materials are compounded to take a synergistic effect, and the western medicine composition has the advantages of small toxic and/or side effects, low cost and no complication, can radically cure rheumatism, ensures low probability of recurrence, is simple in preparation method, short in treatment cycle and good in curative effect, is a safe and effective medicine and protects the health of people.

Compositions and treatment regimen that includes the compositions, suitable for preventing, treating and restoring hearing acuity in a subject are provided. The treatment regimen includes an amount of capsaicin and an amount of a TNF-α inhibitor (such as etanercept) that are delivered relatively simultaneously to a subject. Methods of providing a pretreatment to a subject suitable for preventing hearing loss are also provided. The capsaicin and TNFα inhibitor may be provided in different delivery forms to the subject. Methods of providing a treatment for hearing loss with a TNFα inhibitor alone, such as entanercept, or with capsaicin alone, are also provided.

The invention discloses a western medicinal composition for treating rheumatism. The western medicinal composition comprises, by weight, 2-15 parts of modafinil, 0.1-1 part of methotrexate, 1-3 parts of oxaliplatin and mannitol injection, 0.1-1 part of phosphodiesterase, 1-5 parts of glucocorticoid type drugs, 0.5-2 parts of etanercept, 10-50 parts of purified water, 0.5-1 part of bone peptide tablet, 1-3 parts of donkey-hide gelatin powder, 0.1-1 part of steroid and 1-3 parts of anisodamine. The western medicinal composition has the advantages that the synergistic effect is achieved through compounding of the raw materials, toxic and side effect is small, cost is low, complications are avoided, the rheumatism can be treated thoroughly, and reoccurrence of the rheumatism is avoided; a preparation method of the western medicinal composition is simple, treatment cycle is short, curative effect is good, and the western medicinal composition is safe and effective and protects health of people.

The present invention provides improved Etanercept variants which comprise one (A105E), preferably two (A105E/L106F), amino acid substitutions regarding the Etanercept original amino acid sequence of SEQ ID NO: 3. These variants inhibit TNF activity but fail to neutralize human LTα (hLTα). Thus, they are proposed herein as a great alternative to be used in the clinic for the treatment of autoimmune or inflammatory diseases in which an exacerbated TNF activity is involved, since they prevent the side effects associated to the use of the original Etanercept molecule while retaining the TNF blocking activity.